Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Life Sciences Industry Analysis

UpdatedMay 23, 2026
DataAggregated Company Financials
Companies7
  • 7D4.7%
  • 3M-3.5%
  • 1Y-6.3%
  • YTD-1.4%

The Life Sciences industry is up 4.7% in the last week, with Lonza Group up 5.0%. However, the industry is down 6.3% over the past year. Looking forward, earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the Swiss Life Sciences Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 23 May 2026CHF 48.1bCHF 10.1bCHF 1.1b38.7x44.1x4.8x
Mon, 20 Apr 2026CHF 51.1bCHF 10.1bCHF 1.1b35.3x44.7x5x
Wed, 18 Mar 2026CHF 45.8bCHF 10.1bCHF 1.1b30.8x40x4.5x
Fri, 13 Feb 2026CHF 47.5bCHF 10.1bCHF 1.3b30.9x37.3x4.7x
Sun, 11 Jan 2026CHF 51.4bCHF 10.6bCHF 1.1b32.7x46.7x4.8x
Tue, 09 Dec 2025CHF 49.5bCHF 10.7bCHF 1.1b28.2x45x4.6x
Thu, 06 Nov 2025CHF 48.8bCHF 10.6bCHF 1.1b28.5x44.4x4.6x
Sat, 04 Oct 2025CHF 51.1bCHF 10.6bCHF 1.1b31.7x46.5x4.8x
Mon, 01 Sep 2025CHF 53.0bCHF 10.6bCHF 1.1b34.4x48.1x5x
Wed, 30 Jul 2025CHF 55.1bCHF 10.7bCHF 1.1b35x47.9x5.2x
Fri, 27 Jun 2025CHF 52.5bCHF 10.1bCHF 1.0b33.5x50.5x5.2x
Sun, 25 May 2025CHF 51.8bCHF 10.1bCHF 1.0b30.8x49.9x5.1x
Tue, 22 Apr 2025CHF 49.4bCHF 10.1bCHF 1.0b28.1x48.2x4.9x
Thu, 20 Mar 2025CHF 53.5bCHF 10.1bCHF 1.0b33.4x52.6x5.3x
Sat, 15 Feb 2025CHF 57.1bCHF 10.1bCHF 1.0b36.4x56.7x5.7x
Mon, 13 Jan 2025CHF 54.2bCHF 10.2bCHF 943.4m35.3x57.4x5.3x
Wed, 11 Dec 2024CHF 52.5bCHF 10.2bCHF 943.8m38.5x55.6x5.1x
Fri, 08 Nov 2024CHF 55.7bCHF 10.2bCHF 943.4m43.5x59.1x5.5x
Sun, 06 Oct 2024CHF 54.4bCHF 10.2bCHF 943.3m41.8x57.6x5.3x
Tue, 03 Sep 2024CHF 57.1bCHF 10.2bCHF 937.0m44.9x60.9x5.6x
Thu, 01 Aug 2024CHF 59.9bCHF 10.2bCHF 923.6m45.6x64.9x5.8x
Sat, 29 Jun 2024CHF 52.3bCHF 10.3bCHF 1.0b44.8x52.2x5.1x
Mon, 27 May 2024CHF 54.7bCHF 10.3bCHF 1.0b45.2x54.6x5.3x
Wed, 24 Apr 2024CHF 55.2bCHF 10.3bCHF 1.0b44x55.1x5.4x
Fri, 22 Mar 2024CHF 56.8bCHF 10.2bCHF 1.0b46.1x56.6x5.5x
Sun, 18 Feb 2024CHF 49.9bCHF 10.2bCHF 1.0b45.9x49x4.9x
Tue, 16 Jan 2024CHF 42.5bCHF 9.8bCHF 1.5b31.9x28.4x4.3x
Thu, 14 Dec 2023CHF 39.1bCHF 9.8bCHF 1.5b30.2x26.2x4x
Sat, 11 Nov 2023CHF 39.6bCHF 9.8bCHF 1.5b27.5x26.5x4x
Mon, 09 Oct 2023CHF 47.0bCHF 9.8bCHF 1.5b31.9x31.5x4.8x
Wed, 06 Sep 2023CHF 53.3bCHF 9.8bCHF 1.5b36.9x35.7x5.5x
Fri, 04 Aug 2023CHF 52.4bCHF 9.8bCHF 1.5b35.2x33.9x5.4x
Sun, 02 Jul 2023CHF 55.6bCHF 9.7bCHF 1.6b36.2x34x5.7x
Tue, 30 May 2023CHF 60.0bCHF 9.7bCHF 1.6b37.6x36.7x6.2x
Price to Earnings Ratio

36.7x


Total Market Cap: CHF 60.0bTotal Earnings: CHF 1.6bTotal Revenue: CHF 9.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Life Sciences Industry Price to Earnings3Y Average 46.2x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Life Sciences industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 46.2x.
  • The industry is trading close to its 3-year average PS ratio of 5.1x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences industry have declined 13% per year over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market1.83%
Healthcare3.31%
Life Sciences4.69%
Clinical Research and Equipment4.69%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
LONN Lonza GroupCHF 492.805.0%
+CHF 1.6b		-12.0%PE37.9x
BANB Bachem HoldingCHF 78.504.2%
+CHF 236.0m		60.5%PE39.5x
TECN Tecan GroupCHF 149.4010.9%
+CHF 184.2m		-9.8%PS2.1x
SFZN Siegfried HoldingCHF 80.251.7%
+CHF 59.1m		-16.1%PE20.8x
PPGN PolyPeptide GroupCHF 38.302.5%
+CHF 31.4m		101.4%PS3.6x

Latest News

BANB
CHF 78.50
Bachem Holding
7D
4.2%
1Y
60.5%
Narrative Update • May 22

BANB: Higher Assumed Growth Will Exacerbate Execution Risk And Limit Upside

Analysts have nudged their price targets for Bachem Holding higher, with recent Street research citing revised assumptions for growth, margins and P/E that collectively support a modestly higher fair value approach in CHF terms. Analyst Commentary Recent price target revisions for Bachem Holding sit in a fairly tight range, with updates clustered around the CHF 80 level.
PPGN
CHF 38.30
PolyPeptide Group
7D
2.5%
1Y
101.4%
SFZN
CHF 80.25
Siegfried Holding
7D
1.7%
1Y
-16.1%
Narrative Update • May 17

SFZN: Lowered Expectations And 2026 Guidance Shift Will Support Future Upside Potential

Narrative Update: Siegfried Holding Analysts have adjusted their average price target for Siegfried Holding to CHF 103.91, a change of roughly CHF 0.69. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions informed by the recent mix of higher and lower CHF targets from the Street.
SKAN
CHF 46.95
SKAN Group
7D
1.2%
1Y
-33.0%
Narrative Update • May 15

SKAN: Order Backlog And Dividend Policy Will Support Future Returns

Analysts have kept their CHF 62.50 price target on SKAN Group unchanged, citing a slightly lower discount rate, more cautious assumptions on revenue growth and profit margins, and a higher future P/E multiple in their updated models. What's in the News The Board of Directors plans to propose a dividend of CHF 0.22 per share for approval at the Annual General Meeting on May 7, 2026.
TECN
CHF 149.40
Tecan Group
7D
10.9%
1Y
-9.8%
LONN
CHF 492.80
Lonza Group
7D
5.0%
1Y
-12.0%
XLS
CHF 21.20
Xlife Sciences
7D
-0.9%
1Y
5.0%